Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IMC-U120AI
- Development stage
- Preclinical
- Lead developer
- Immunocore
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Fc Fusion Proteins → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
IMC-U120AI is a bispecific, recombinant fusion protein designed as a CD1a-tethered PD1 agonist, developed by Immunocore. It is the first non-HLA-restricted (universal) candidate from Immunocore’s ImmTAAI platform, intended for tissue-specific down-modulation of the immune system in autoimmune diseases. The drug targets CD1a, an HLA-like protein expressed on skin and mucosal antigen-presenting cells such as Langerhans cells, which play a key role in allergic inflammation seen in atopic dermatitis and potentially other immune-mediated diseases. Its dual mechanism of action involves blocking CD1a to suppress activation by lipid antigens and activating PD1 on T cells to suppress activation by peptide antigens. The initial indication under development is atopic dermatitis[1][3][5][6].
- Other names
- IMC U 120AI
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)CD1A (T-cell surface glycoprotein CD1a)
Beyond the preview
Go deeper on IMC-U120AI.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IMC-U120AI.